Is Lakewood-Amedex Biotherapeutics Inc. Common Stock (LABT) a Buy, Sell, or Hold?
NASDAQ : LABT
Lakewood-Amedex Biotherapeutics Inc. Common Stock
$1.92 USD
-$0.01 (-0.52%)
- Volume
- 44.49K
- Average Volume
- 298.86K
- Market Capitalization
- $900.32K
- P/E Ratio
- Dividend Yield
- %
- Price Target
- Year High
- $9.26
- Year Low
- $0.37
- Day High
- —
- Day Low
- —
- Payout Ratio
- Current Ratio
Company Overview
NASDAQ
Kelvin Cooper
Biotechnology
Healthcare
LABT
5
US
USD
Liquidity Metrics
Sales & Valuation
-$
Profitability
-$
%
%
%
%
P/E Metrics
Analyst Price Target & Rating
2/5
0 Analysts
%
Financial Health Scores
No financial score data available.
Key Metrics (TTM)
-$
0.00
0.00%
0.00%
%
%
$0.00
0 days
Company Executives
| Name | Title |
|---|---|
| Thomas Balzer | Chief Medical Officer & SVP of Clinical Development |
| Peter F. Ceccacci | CFO & VP of Administration |
| Tara Endress | Project Manager & Accounting Manager |
| Kelvin Cooper | CEO, SVP of Research & Development and Director |
| Daniel Kontoh-Boateng | Investor Relations |
Poll Results
No votes yet today — be the first to share your view!
About Lakewood-Amedex Biotherapeutics Inc. Common Stock (NASDAQ:LABT) Stock
This biopharmaceutical company is dedicated to developing innovative antimicrobial therapies. Its array of anti-infective products is designed to tackle specific viral conditions, including avian influenza, Epstein-Barr Virus (EBV), and hepatitis B and C. Established by Roderic Dale on July 11, 2006, the firm maintains its principal office in Bradenton, Florida. ...
Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) vs. MBX Biosciences (NASDAQ:MBX) Critical Survey
2026-07-17 05:49:10
MBX Biosciences (NASDAQ: MBX - Get Free Report) and Lakewood-Amedex Biotherapeutics (NASDAQ: LABT - Get Free Report) are both manufacturing companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends and valuation. Valuation and Earnings This table compares MBX Biosciences
2026-07-15 08:02:00
Nu-3 is a gel formulation of a Bisphosphocin® compound targeting the topical treatment of infected diabetic foot ulcers with low likelihood of producing systemic side effects. SARASOTA, Fla.
2026-07-07 08:02:00
Company highlights its differentiated Bisphosphocin ® platform and lead clinical candidate Nu-3 as innovative approaches to addressing microbial infections and the risk of resistance development SARASOTA, Fla., July 7, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT, the "Company"), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, announced its support for the reintroduction of the bipartisan Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act, legislation designed to encourage the development of novel therapies to address the growing global threat of antimicrobial resistance (AMR).
Lakewood-Amedex Biotherapeutics Announces World-Renowned Expert David G. Armstrong, M.D.
2026-06-25 08:02:00
Leading clinician and surgeon to also serve as Scientific Advisor for Lakewood-Amedex Biotherapeutics' iDFU program SARASOTA, Fla., June 25, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT, the "Company"), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, today announced that David G.
2026-06-22 08:02:00
New patent enhances global IP footprint and pipeline expansion opportunities SARASOTA, Fla., June 22, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT, the "Company"), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, today announced the expansion of the Company's patent portfolio with the issuance of a new patent in Australia protecting Bisphosphocin® compounds that are being explored in a range of antimicrobial infections including complicated urinary tract infections and pulmonary infections.
Lakewood-Amedex Biotherapeutics to Present at Life Sciences Virtual Investor Forum
2026-06-16 08:02:00
SARASOTA, Fla., June 16, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT, the "Company"), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, today announced that Kelvin Cooper, Ph.D.
2026-05-27 08:02:00
Patent portfolio now includes 71 granted patents and 28 pending patent applications, covering composition of matter, formulation, and use patents SARASOTA, Fla., May 27, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT, the "Company"), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, today announced an expansion of its global intellectual property portfolio with the issuance of two patents, one each in Australia and New Zealand respectively.
Lakewood-Amedex Stock Falls Despite Positive Nu-3 Manufacturing Update
2026-05-18 10:11:52
Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT) shares were trading higher Monday but have since reversed and begun trading lower after the company announced data for Nu-3.
Frequently Asked Questions
-
What is the current Lakewood-Amedex Biotherapeutics Inc. Common Stock (LABT) stock price?
-
Lakewood-Amedex Biotherapeutics Inc. Common Stock(NASDAQ:LABT) stock price is $1.92 in the last trading session. During the trading session, LABT stock reached the peak price of $9.26 while $0.37 was the lowest point it dropped to. The percentage change in LABT stock occurred in the recent session was --0.52% while the dollar amount for the price change in LABT stock was -$0.01.
-
LABT's industry and sector of operation?
-
The NASDAQ listed LABT is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of LABT?
-
Thomas Balzer | Chief Medical Officer & SVP of Clinical Development
Peter F. Ceccacci | CFO & VP of Administration
Tara Endress | Project Manager & Accounting Manager
Kelvin Cooper | CEO, SVP of Research & Development and Director
Daniel Kontoh-Boateng | Investor Relations -
How many employees does LABT have?
-
Number of LABT employees currently stands at 5. LABT operates from 8031 Cooper Creek Blvd., Unit 103, University Park, FL 34201, US.
-
Link for LABT official website?
-
Official Website of LABT is: http://www.lakewoodamedex.com
-
How do I contact LABT?
-
LABT could be contacted at phone #1-941-225-2515 and can also be accessed through its website. LABT operates from 8031 Cooper Creek Blvd., Unit 103, University Park, FL 34201, US.
-
How many shares of LABT are traded daily?
-
The average number of LABT shares traded daily for last 3 months was 298.86K.
-
What is the market cap of LABT currently?
-
The market value of LABT currently stands at $900.32K with its latest stock price at $1.92